Skip to main content

Table 3 Univariate analysis of MSHFS in patients undergoing PLD chemotherapy

From: Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters

Factor   NMHFS(n = 255) MSHFS(n = 206) P
Age   51.10 ± 9.94 51.17 ± 9.10 0.936
BMI   23.44, 21.61–25.71 24.154, 22.21–26.84 0.028*
PLD dose intensity   30.18, 26.79–32.20 32.47, 30.50–35.71 <0.001**
Baseline ALT   15, 11–19 16, 12–23 0.012*
Baseline AST   19, 17–22 20, 12–24 0.023*
Baseline GGT   18, 14–24 21, 14–28 0.101
Baseline TBIL   12.600, 10–16.1 13.400, 10–16.85 0.297
Baseline MONO   0.360, 0.30–0.45 0.400, 0.32–0.46 0.058
Baseline NLR   1.800, 1.36–2.45 1.655, 1.31–2.28 0.231
Baseline PLR   133.000, 109–170 129.000, 106–171 0.890
Baseline CA153 8.800, 7–12.6 10.000, 6.93–15.0 0.106
Baseline CEA 1.600, 1–2.3 1.700, 1–2.67 0.345
ECOG score     0.264
0 251 (98.4) 205 (99.5)  
1 4 (1.6) 1 (0.5)  
Hypertension disease     0.778
No 231 (90.6) 185 (89.8)  
Yes 24 (9.4) 21 (10.2)  
Diabetes     0.051
No 232 (91.0) 197 (95.6)  
Yes 23 (9.0) 9 (4.4)  
Cholecystitis     0.113
No 245 (96.1) 191 (92.7)  
Yes 10 (3.9) 15 (7.3)  
History of gallstones     0.003**
No 250 (98.0) 190 (92.2)  
Yes 5 (2.0) 16 (7.8)  
Peripheral blood circulation     <0.001**
Poor 88 (34.5) 34 (16.5)  
Good 167 (65.5) 171 (83.5)  
Sweat excretion     <0.001**
Normal 227 (89.0) 151 (73.3)  
Excessive 28 (11.0) 55 (26.7)  
Allergy or not     0.905
No 242 (94.9) 196 (95.1)  
Yes 13 (5.1) 10 (4.9)  
Viral hepatitis     0.750
No 237 (92.9) 193 (93.7)  
Yes 18 (7.1) 13 (6.3)  
With or without tumor     0.040*
No 194 (76.1) 139 (67.5)  
Yes 61 (23.9) 67 (32.5)  
Ki-67     0.921
Low 88 (34.5) 72 (34. 9)  
High 167 (65.5) 134 (65.1)  
ER     0.406
Negative 81 (31.8) 73 (35.4)  
Positive 174 (68.2) 133 (64.6)  
PR     0.061
Negative 98 (38.4) 97 (47.1)  
Positive 157 (61.6) 109 (52.9)  
HER2     0.001**
Negative 208 (81.4) 141 (68.4)  
Positive 47 (18.4) 65 (31.6)  
  1. * p < 0.05 ** p < 0.01
  2. Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, ECOG eastern cooperative oncology group, ER estrogen receptor, GGT γ-glutamyl transpeptidase, HER2 human epidermalgrowth factor receptor-2, Ki-67 antigen identified by monoclonal antibody Ki-67, MSHFS moderate to severe hand-foot syndrome, MONO monocytes, NLR neutrophil-lymphocyte ratio, NMHFS none and mild hand-foot syndrome, PLR platelet-lymphocyte ratio, PR progesterone receptor, TBIL total bilirubin
\